

JCWSCS 0 5 FEB 2004 FEB-05-2004 THU 01:59 PM SENNIGER POWERS LEAVITT

T19 Recid PET/PTO 0 5 FEB 2004 01

Law Offices of SENNIGER, POWERS, LEAVITT AND ROEDEL One Metropolitan Square, 16th Floor St. Louis, Missouri 63102

Telephone (314) 231-5400 Facsimile (314) 231-4342

FACSIMILE TRANSMITTAL COVER SHEET

DATE: February 5, 2004 ATTORNEY DOCKET #: 3167/52/US (PHA 2005)
PTO FACSIMILE NUMBER: (703) 746-9195
PLEASE DELIVER THIS FACSIMILE TO:
Office of Initial Patent Examination's Filing Receipt Corrections
THIS FACSIMILE IS BEING SENT BY: Kathryn J. Doty, Esq.
NUMBER OF PAGES: 5 INCLUDING COVER SHEET
TIME SENT: /.58 pm OPERATOR'S NAME M. Susan Clements (CDT)
CERTIFICATION OF FACSIMILE TRANSMISSION
I hereby certify that these papers are being transmitted via facsimile to the Commissioner for Patents on the date shown below.
M. Susan Clements
Typed or printed name of person signing certification
M. Susan Clements February 5, 2004
Signature Date
Type of papers transmitted: Request for Corrected Filing Receipt
Applicant's Name: John P. McKearn, et al.
Serial No. (Control No.): 09/857,994 Examiner:
Filing Date: October 5, 2001 Art Unit: 1646
Application Title: METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA
IF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS POSSTBLE. CONFIRMING NUMBER IS (314) 231-5400.

Art Unit 1617

Senniger, Powers, Leavitt & Roedel

Panents, Trademarks, Copyrights. Technology Law, Antiteuse, Litigation Attorneys at Law

One Metropulitan Square, 16th Floor Ssint Louis, Missouri 63102

> Telephone: 314-231-5400 Famimile: 314-231-4342

> > www.sconiger.com

Kathryn J. Doty kdoty@senniger.com

February 5, 2004

Application of John P. McKearn et al.

Serial No. 09/857,994

Filed October 5, 2001

Confirmation No. 4028

METHOD OF USING INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY

Attorney Docket No. PHA 2005 (3167/6Z/US)

Office of Initial Patent Examination's Customer Service Center Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir

Our firm recently took over the prosecution of the above-referenced patent application. The filing receipt was received (date mailed) October 23, 2001. On February 7, 2002 a Request for Corrected Filing Receipt was filed, however, to date we have not received a Corrected Filing Receipt. The receipt shows the priority information as "This Application is a 371 of PCT/US99/30670 12/22/1999"; whereas the correct priority information is "This Application is a 371 of PCT/US99/30670 12/22/1999 and Claims Benefit of 60/113,786 12/28/98".

A copy of the Filing Receipt with the changes noted thereon is enclosed. Also enclosed is a copy our executed Power of Attorney.

Please send us a corrected filing receipt.

Respectfully submitted,

Kathryn J. Doty, Reg. No. 40,593

KJD/msc *Enclosure

Patricia G. Keller, Ph.D. (w/o Encl.) CC:

PAGE 2/5 * RCVD AT 2/5/2004 2:54:59 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/0 * DNIS:7469195 * CSID:3145881357 * DURATION (mm-ss):01-32

Page 1 of 2



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS	J
AFFECATION				CU-2561		115	2	
00/857 004	10/05/2001	1646	2700	RJS		117	2	

CONFIRMATION NO. 4028

FILING RECEIPT

OCDOOOOOOOGSSOS88

Richard J Streit Ladas & Parry Suite 1200 224 South Michigan Avenue Chicago, IL 60604

Date Mailed: 10/23/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another, Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

John P. McKearn, Glencoe, MO; Gary Gordon, Highland, IL; James J. Cunningham, Chicago, IL; Stephen T. Gately, Palatine, IL; Alane T. Koki, Beaufort, MO; Jaime L. Masferrer, Ballwin, MO;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/30670 12/22/1999
AND CLA. MS BENEFIT OF 60/113,786 12/23/98

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

Method of using an integrin antagonist and one or more antineoplastic agents as a combination

Page 2 of 2

therapy in the treatment of neoplasia

Preliminary Class

424

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).